Department of Otolaryngology-Head and Neck Surgery, University of California, Irvine, Orange, California.
Department of Otolaryngology-Head and Neck Surgery, University of California, Irvine, Orange, California.
Ann Allergy Asthma Immunol. 2023 Sep;131(3):327-332. doi: 10.1016/j.anai.2023.04.013. Epub 2023 Apr 23.
The high prescription drug cost in the United States may negatively affect patient prognosis and treatment compliance.
To fill the knowledge gap and inform clinicians regarding rhinology medications price changes by evaluating trends in price changes of highly used nasal sprays and allergy medications.
The 2014-2020 Medicaid National Average Drug Acquisition Cost database was queried for drug pricing information for the following classes of medications: intranasal corticosteroids, oral antihistamines, antileukotrienes, intranasal antihistamines, and intranasal anticholinergics. Individual medications were identified by Food and Drug Administration-assigned National Drug Codes. Per unit, drug prices were analyzed for average annual prices, average annual percentage price changes, and inflation-adjusted annual and composite percentage price changes.
Beclometasone (Beconase AQ, 56.7%, QNASL, 77.5%), flunisolide (Nasalide, -14.6%), budesonide (Rhinocort Aqua, -1.2%), fluticasone (Flonase, -6.8%, Xhance, 11.7%), mometasone (Nasonex, 38.2%), ciclesonide (Omnaris, 73.8%), combination azelastine and fluticasone (Dymista, 27.3%), loratadine (Claritin, -20.5%), montelukast (Singulair, 14.5%), azelastine (Astepro, 21.9%), olopatadine (Patanase, 27.3%), and ipratropium bromide (Atrovent, 56.6%) had an overall change in inflation-adjusted per unit cost between 2014 and 2020 (% change). Of 14 drugs evaluated, 10 had an increase in inflation-adjusted prices, for an average increase of 42.06% ± 22.27%; 4 of 14 drugs had a decrease in inflation-adjusted prices, for an average decrease of 10.78% ± 7.36%.
The rising cost of highly used medications contributes to increased patient acquisition costs and may pose barriers of drug adherence to particularly vulnerable populations.
美国的高处方药成本可能对患者的预后和治疗依从性产生负面影响。
通过评估高用量鼻腔喷雾剂和过敏药物价格变化趋势，填补有关鼻科学药物价格变化的知识空白，并为临床医生提供信息。
查询了 2014 年至 2020 年 Medicaid 国家平均药物收购成本数据库，以获取以下类别的药物定价信息：鼻腔皮质类固醇、口服抗组胺药、抗白三烯、鼻腔内抗组胺药和鼻腔内抗胆碱能药。通过食品和药物管理局分配的国家药物代码识别个别药物。按单位分析药物价格的平均年度价格、平均年度价格变化百分比、通货膨胀调整后的年度和综合价格变化百分比。
倍氯米松（Beconase AQ，56.7%，QNASL，77.5%）、氟尼缩松（Nasalide，-14.6%）、布地奈德（Rhinocort Aqua，-1.2%）、氟替卡松（Flonase，-6.8%，Xhance，11.7%）、莫米松（Nasonex，38.2%）、环索奈德（Omnaris，73.8%）、盐酸氮䓬斯汀和氟替卡松（Dymista，27.3%）、氯雷他定（Claritin，-20.5%）、孟鲁司特（Singulair，14.5%）、氮䓬斯汀（Astepro，21.9%）、奥洛他定（Patanase，27.3%）和异丙托溴铵（Atrovent，56.6%）在 2014 年至 2020 年期间，其单位成本的通货膨胀调整后总体变化（变化百分比）。在评估的 14 种药物中，有 10 种药物的通货膨胀调整后价格上涨，平均涨幅为 42.06%±22.27%；有 4 种药物的通货膨胀调整后价格下降，平均降幅为 10.78%±7.36%。
高用量药物成本的上升导致患者获得成本增加，可能对特别是弱势群体的药物依从性造成障碍。
